(NASDAQ: PLRX) Pliant Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.86%.
Pliant Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast PLRX's revenue for 2027 to be $7,319,880,045, with the lowest PLRX revenue forecast at $2,987,718,638, and the highest PLRX revenue forecast at $11,652,041,451. On average, 3 Wall Street analysts forecast PLRX's revenue for 2028 to be $19,680,915,273, with the lowest PLRX revenue forecast at $7,898,256,813, and the highest PLRX revenue forecast at $42,777,835,804.
In 2029, PLRX is forecast to generate $44,641,256,139 in revenue, with the lowest revenue forecast at $15,574,225,890 and the highest revenue forecast at $81,130,124,857.